# Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

> **NCT01076530** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Embryonal Tumor
- Childhood Central Nervous System Germinoma
- Childhood Central Nervous System Mixed Germ Cell Tumor
- Childhood Central Nervous System Teratoma
- Childhood Central Nervous System Yolk Sac Tumor
- Childhood Choroid Plexus Tumor
- Childhood Craniopharyngioma
- Childhood Ependymoblastoma
- Childhood Grade I Meningioma
- Childhood Grade II Meningioma
- Childhood Grade III Meningioma
- Childhood High-grade Cerebellar Astrocytoma
- Childhood High-grade Cerebral Astrocytoma
- Childhood Infratentorial Ependymoma
- Childhood Low-grade Cerebellar Astrocytoma
- Childhood Low-grade Cerebral Astrocytoma
- Childhood Medulloepithelioma
- Childhood Mixed Glioma
- Childhood Oligodendroglioma
- Childhood Supratentorial Ependymoma
- Extra-adrenal Paraganglioma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Central Nervous System Embryonal Tumor
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Ependymoma
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Pineoblastoma
- Recurrent Childhood Spinal Cord Neoplasm
- Recurrent Childhood Subependymal Giant Cell Astrocytoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma

## Interventions

- **DRUG:** vorinostat
- **DRUG:** temozolomide
- **OTHER:** diagnostic laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01076530
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-10
- **Final completion:** —
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2013-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01076530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01076530, "Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01076530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*